Long-term use of an LH-RH agonist in the management of uterine leiomyomas: A study of 17 cases

M. George, C. Lhomme, J. Lefort, C. Gras, A. M. Comaru-Schally, Andrew V Schally

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days. The microcapsules were designed to release 100 μg/day for 30 days. The mean duration of treatment was 4.7 months (range, 1-11). In all patients, the pituitary-ovarian axis was suppressed after 1 month of treatment, and mean serum estradiol levels fell to 17.3 pg/mL (range, 5-80). There were no significant changes in serum LH and FSH levels. Fifteen patients (83%) experienced an improvement of such symptoms as abdominal pain and bleeding. Enlarged uteri decreased in 81% of patients during the treatment, and in 38% of them the decrease in uterine volume was more than 50%. Among the 12 myomas found in 10 women, 2 disappeared and 9 decreased in volume during the treatment; for 7 myomas the decrease was more than 50%. After Decapeptyl, eight patients did not require any additional therapy, four underwent surgery, and the others were treated with progestins. The side effects were mild, consisting mainly of hot flushes. Our findings suggest that Decapeptyl may be useful for the treatment of uterine myomas.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalInternational Journal of Fertility
Volume34
Issue number1
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Leiomyoma
Triptorelin Pamoate
Gonadotropin-Releasing Hormone
Myoma
Capsules
Therapeutics
Gynecological Examination
Progestins
Serum
Abdominal Pain
Uterus
Estradiol
Ultrasonography
Hemorrhage

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Long-term use of an LH-RH agonist in the management of uterine leiomyomas : A study of 17 cases. / George, M.; Lhomme, C.; Lefort, J.; Gras, C.; Comaru-Schally, A. M.; Schally, Andrew V.

In: International Journal of Fertility, Vol. 34, No. 1, 01.01.1989, p. 19-24.

Research output: Contribution to journalArticle

George, M, Lhomme, C, Lefort, J, Gras, C, Comaru-Schally, AM & Schally, AV 1989, 'Long-term use of an LH-RH agonist in the management of uterine leiomyomas: A study of 17 cases', International Journal of Fertility, vol. 34, no. 1, pp. 19-24.
George, M. ; Lhomme, C. ; Lefort, J. ; Gras, C. ; Comaru-Schally, A. M. ; Schally, Andrew V. / Long-term use of an LH-RH agonist in the management of uterine leiomyomas : A study of 17 cases. In: International Journal of Fertility. 1989 ; Vol. 34, No. 1. pp. 19-24.
@article{d1b55ab54e3c4cbc84b4ec88d7b74f7e,
title = "Long-term use of an LH-RH agonist in the management of uterine leiomyomas: A study of 17 cases",
abstract = "Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days. The microcapsules were designed to release 100 μg/day for 30 days. The mean duration of treatment was 4.7 months (range, 1-11). In all patients, the pituitary-ovarian axis was suppressed after 1 month of treatment, and mean serum estradiol levels fell to 17.3 pg/mL (range, 5-80). There were no significant changes in serum LH and FSH levels. Fifteen patients (83{\%}) experienced an improvement of such symptoms as abdominal pain and bleeding. Enlarged uteri decreased in 81{\%} of patients during the treatment, and in 38{\%} of them the decrease in uterine volume was more than 50{\%}. Among the 12 myomas found in 10 women, 2 disappeared and 9 decreased in volume during the treatment; for 7 myomas the decrease was more than 50{\%}. After Decapeptyl, eight patients did not require any additional therapy, four underwent surgery, and the others were treated with progestins. The side effects were mild, consisting mainly of hot flushes. Our findings suggest that Decapeptyl may be useful for the treatment of uterine myomas.",
author = "M. George and C. Lhomme and J. Lefort and C. Gras and Comaru-Schally, {A. M.} and Schally, {Andrew V}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "19--24",
journal = "International Journal of Fertility",
issn = "0020-725X",
publisher = "MSP International",
number = "1",

}

TY - JOUR

T1 - Long-term use of an LH-RH agonist in the management of uterine leiomyomas

T2 - A study of 17 cases

AU - George, M.

AU - Lhomme, C.

AU - Lefort, J.

AU - Gras, C.

AU - Comaru-Schally, A. M.

AU - Schally, Andrew V

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days. The microcapsules were designed to release 100 μg/day for 30 days. The mean duration of treatment was 4.7 months (range, 1-11). In all patients, the pituitary-ovarian axis was suppressed after 1 month of treatment, and mean serum estradiol levels fell to 17.3 pg/mL (range, 5-80). There were no significant changes in serum LH and FSH levels. Fifteen patients (83%) experienced an improvement of such symptoms as abdominal pain and bleeding. Enlarged uteri decreased in 81% of patients during the treatment, and in 38% of them the decrease in uterine volume was more than 50%. Among the 12 myomas found in 10 women, 2 disappeared and 9 decreased in volume during the treatment; for 7 myomas the decrease was more than 50%. After Decapeptyl, eight patients did not require any additional therapy, four underwent surgery, and the others were treated with progestins. The side effects were mild, consisting mainly of hot flushes. Our findings suggest that Decapeptyl may be useful for the treatment of uterine myomas.

AB - Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days. The microcapsules were designed to release 100 μg/day for 30 days. The mean duration of treatment was 4.7 months (range, 1-11). In all patients, the pituitary-ovarian axis was suppressed after 1 month of treatment, and mean serum estradiol levels fell to 17.3 pg/mL (range, 5-80). There were no significant changes in serum LH and FSH levels. Fifteen patients (83%) experienced an improvement of such symptoms as abdominal pain and bleeding. Enlarged uteri decreased in 81% of patients during the treatment, and in 38% of them the decrease in uterine volume was more than 50%. Among the 12 myomas found in 10 women, 2 disappeared and 9 decreased in volume during the treatment; for 7 myomas the decrease was more than 50%. After Decapeptyl, eight patients did not require any additional therapy, four underwent surgery, and the others were treated with progestins. The side effects were mild, consisting mainly of hot flushes. Our findings suggest that Decapeptyl may be useful for the treatment of uterine myomas.

UR - http://www.scopus.com/inward/record.url?scp=0024419050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024419050&partnerID=8YFLogxK

M3 - Article

C2 - 2565299

AN - SCOPUS:0024419050

VL - 34

SP - 19

EP - 24

JO - International Journal of Fertility

JF - International Journal of Fertility

SN - 0020-725X

IS - 1

ER -